• Explore /
  • Poster
  • / Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer.

Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer.

Abstract Poster

Authors

null

Mariela A. Blum Murphy

The University of Texas MD Anderson Cancer Center, Houston, TX;

Mariela A. Blum Murphy , Jaffer A. Ajani , Brian Andrew Van Tine , Jeffrey Melson Clarke , Marcus O. Butler , Donald P. Lawrence , Melissa Lynne Johnson , Andres Cervantes , Victor Moreno , David S. Hong , Francine Elizabeth Brophy , Jean-Marc Navenot , Quan Lin , Jose Saro , Elliot Norry

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04044859

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 349)

DOI

10.1200/JCO.2023.41.4_suppl.349

Abstract #

349

Poster Bd #

E10

Abstract Disclosures

Similar Posters

First Author: Keitaro Shimozaki

First Author: Ilya Tsimafeyeu

First Author: Daisuke Takahari

First Author: Kensei Yamaguchi